Placebo IM Pre-treatment  Post-treatment Pre-treatment Post-treatment Petechiae, Denuned areas and Reddened folds   1.4 ± 1.6 7.4 ± 11.0 1.3 ± 1.4 2.9 ± 3.0* Mucosal breaks and ulcers 0.2 ± 0.9 1.9 ± 4.8 0.2 ± 0.4 1.6 ± 3.0 Total 1.6 ± 1.9 9.4 ± 15.6 1.4 ± 1.5 4.5 ± 5.5 (* p<0.05 compared to placebo）

Table 2: Comparison of the mean number of mucosal injuries per subject between the placebo and the irsogladine maleate (IM) group at post-treatment.